P130018/S006: ProACT Adjustable Continence Therapy for Men
FDA’s recorded scope: addition of a post-cure process to the manufacturing procedure for the implantable device component
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name Uromedica, Inc.. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 3, 2025 to Feb 11, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code EZY appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P130018, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1840 Berkshire Ln. N., Plymouth, MN, 55441. Recorded on P130018/S006, decision dated Feb 11, 2026.
FDA’s recorded scope: addition of a post-cure process to the manufacturing procedure for the implantable device component
FDA’s recorded scope: for the addition of four potential adverse events and updates to the MRI Information section of the instructions for use
FDA’s recorded scope: Approval of the modifications to the study protocol including expansion of the study to 10-14 study sites and modifications to the Informed Consent Form for the post-approval study.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProACT Adjustable Continence Therapy for MenP130018/S006 | Uromedica, Inc. | PMA supplement | Feb 11, 2026 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S005 | Uromedica, Inc. | PMA supplement | Jan 28, 2026 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S004 | Uromedica, Inc. | PMA supplement | Oct 3, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.